Hematological findings and complications of COVID-19
Terpos E., Ntanasis-Stathopoulos I., E`lalami M. I. Zh., Kastritis E., Sergentanis T. N., Politou M., Psaltopoulou T., Gerotziafas G., Dimopoulos M. A.
American Journal of Hematology
Vol.95, Issue7, P. 834-847
Опубликовано: 2020
Тип ресурса: Обзор
Аннотация:
COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase,
Ключевые слова:
biological marker; C reactive protein; ferritin; procalcitonin; anticoagulant agent; biological marker; C reactive protein; cytokine; ferritin; fibrin degradation product; fibrin fragment D; adverse event; biochemistry; blood cell count; blood clotting disorder; clinical feature; coronavirus disease 2019; epidemic; hematology; hematopoietic stem cell; human; infection risk; leukocytosis; leukopenia; lymphocytopenia; mortality risk; platelet count; platelet lymphocyte ratio; priority journal; prognosis; Review; risk factor; Severe acute respiratory syndrome coronavirus 2; thrombocytopenia; Betacoronavirus; blood; blood clotting test; blood donor; complication; Coronavirus infection; cytokine release syndrome; disseminated intravascular clotting; early diagnosis; laboratory technique; lymphocytopenia; meta analysis (topic); pandemic; risk; thrombophilia; venous thromboembolism; virus pneumonia; Anticoagulants; Betacoronavirus; Biomarkers; Blood Coagulation Tests; Blood Donors; C-Reactive
Язык текста: Английский
ISSN: 1096-8652
Terpos E.
Ntanasis-Stathopoulos I.
E`lalami M. I. Zh. Mule` Ismail Zhabran 1958-
Kastritis E.
Sergentanis T. N.
Politou M.
Psaltopoulou T.
Gerotziafas G.
Dimopoulos M. A.
Терпос Е.
Нтанасис-Статхопоулос И.
Элалами М. И. Ж. Мулэ Исмаил Жабран 1958-
Кастритис Е.
Сергентанис Т. Н.
Политоу М.
Псалтопоулоу Т.
Геротзиафас Г.
Димопоулос М. А.
Hematological findings and complications of COVID-19
Текст визуальный непосредственный
American Journal of Hematology
John Wiley & Sons
Vol.95, Issue7 P. 834-847
2020
Обзор
biological marker C reactive protein ferritin procalcitonin anticoagulant agent biological marker C reactive protein cytokine ferritin fibrin degradation product fibrin fragment D adverse event biochemistry blood cell count blood clotting disorder clinical feature coronavirus disease 2019 epidemic hematology hematopoietic stem cell human infection risk leukocytosis leukopenia lymphocytopenia mortality risk platelet count platelet lymphocyte ratio priority journal prognosis Review risk factor Severe acute respiratory syndrome coronavirus 2 thrombocytopenia Betacoronavirus blood blood clotting test blood donor complication Coronavirus infection cytokine release syndrome disseminated intravascular clotting early diagnosis laboratory technique lymphocytopenia meta analysis (topic) pandemic risk thrombophilia venous thromboembolism virus pneumonia Anticoagulants Betacoronavirus Biomarkers Blood Coagulation Tests Blood Donors C-Reactive
COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase,